Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Sold by Ritholtz Wealth Management

Ritholtz Wealth Management trimmed its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 37.7% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 21,791 shares of the company’s stock after selling 13,163 shares during the quarter. Ritholtz Wealth Management’s holdings in Teva Pharmaceutical Industries were worth $335,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Oarsman Capital Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth about $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth about $44,000. Compagnie Lombard Odier SCmA bought a new position in Teva Pharmaceutical Industries in the 1st quarter worth about $54,000. Versant Capital Management Inc increased its stake in shares of Teva Pharmaceutical Industries by 437.8% in the first quarter. Versant Capital Management Inc now owns 5,297 shares of the company’s stock valued at $81,000 after purchasing an additional 4,312 shares during the period. Finally, IFP Advisors Inc raised its holdings in shares of Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after buying an additional 1,960 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on TEVA shares. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $21.00 to $23.00 in a report on Monday, May 12th. The Goldman Sachs Group started coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a “buy” rating and a $24.00 target price on the stock. Truist Financial began coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a “buy” rating and a $25.00 price target for the company. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. Finally, Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Nine research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Buy” and a consensus price target of $24.44.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the sale, the executive vice president now owns 9,989 shares of the company’s stock, valued at $170,012.78. This trade represents a 38.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $16.97 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.74 and a debt-to-equity ratio of 2.59. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a market cap of $19.46 billion, a PE ratio of -14.75, a PEG ratio of 0.88 and a beta of 0.60. The stock’s 50-day moving average price is $16.32 and its two-hundred day moving average price is $17.42.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period last year, the firm posted $0.48 earnings per share. On average, analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.